期刊文献+

聚乙二醇干扰素α-2a治疗合并自身免疫现象慢性丙型肝炎的相关问题探讨 被引量:1

Response to PEG-IFN α-2a by chronic hepatitis C patients with autoimmune features
下载PDF
导出
摘要 目的探讨HCV感染诱导的自身免疫现象对PEG-IFNα-2a治疗的反应性及自身抗体水平在PEG-IFNα-2a治疗前后的变化,了解PEG-IFNα-2a诱发的自身免疫现象的规律及临床意义。方法采用荧光定量聚合酶链反应和聚合酶链反应-微板核酸杂交-ELASA法及间接免疫荧光法对24例慢性丙型肝炎(CHC)合并自身抗体患者、41例CHC不合并自身抗体患者进行PEG-IFNα-2a治疗前后自身抗体的发生率以及其与PEG-IFNα-2a治疗应答的关系分析。结果 65例接受PEG-IFNα-2a治疗后未出现自身抗体者对干扰素的应答相对较好,治疗前合并自身抗体的CHC患者对PEG-IFNα-2a的应答相对较差。自身抗体检出率在PEG-IFNα-2a治疗后有所升高,但治疗结束6个月后下降,且低于治疗前的阳性检出率。治疗前ANA、SMA阳性或治疗后出现ANA、SMA抗体者的应答率低。LKMA1、TMA、TGA与治疗应答率无明显关系。结论 CHC合并自身抗体患者对PEG-IFNα-2a治疗的应答率低于不合并自身抗体的CHC患者,PEG-IFNα-2a治疗过程中出现或升高的自身抗体可在治疗停止6个月后下降或消失。 Objective Study on a response to PEG-IFN α-2a in chronic hepatitis C(CHC) patients with autoimmune features and analyze the variation of serum auto antibody level before and after treatment.Methods HCV,HCV genotype,AMA,SMA,TGA and TMA were analyzed in 24 autoantibody positive and 41 autoantibody negative CHC patients before and after PEG-IFN α-2a treatment.Sandwich hybridization microplate,fluorescence quantification PCR and Indirect Immunofluorescence techniques were used.Results The response rate was higher in 65 autoantibody positive than autoantibody negative CHC patients before and after PEG-IFN α-2a treatment.The autoantibody reappeared with increased level at the end of PEG-IFN α-2a treatment,but decreased 6 months later to even lower than the pretreatment level.Response rates to PEG-IFN α-2a were significantly lower in patients with ANA and SMA compared to CHC patients without ANA and SMA.The response rate to PEG-IFN α-2a was not statistically significant between TMA and TGA.Conclusion Autoantibody positive CHC patients show lower response rate to PEG-IFN α-2a than autoantibody negative CHC patients.PEG-IFN α-2a treatment may result in the appearance and increase autoantibody level during the treatment of serious autoimmune disease,but may be recovered 6 months after the end of PEG-IFN α-2a treatment.
出处 《临床肝胆病杂志》 CAS 2010年第4期374-376,共3页 Journal of Clinical Hepatology
关键词 自身免疫 干扰素类 自身抗体 肝炎 丙型 慢性 autoimmunity interferons autoantibodies hepatitis C chronic
  • 相关文献

参考文献2

二级参考文献60

  • 1Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G,Goncales FL Jr, Haussinger D, Diago M, Carosi G, Dhumeaux D, Craxi A, Lin A, Hoffman J,Yu J. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347:975-982.
  • 2Fattovich G, Giustina G, Favarato S, Ruol A. A survey of adverse events in 11241 patients with chronic viral hepatitis treated with alpha interferon. J Hepatol 1996; 24:38-47.
  • 3Daleko$ GN, Christodoulou D, Kistis K, Zervou EK, Hatzis J,Tsianos EV. A prospective evaluation of dermatological sideeffects during alpha-interferon therapy for chronic viral hepatitis. Eur J Gastroenterol Hepatol 1998; 10:933-939.
  • 4Clifford BD, Donahue D, Smitt~ L, Cable E, Luttig B, Manns M, Bonkovsky HL. High prevalence of serological markers of autoimmunity in patients with chronic hepatitis C. Hepatology 1995; 21:613-619.
  • 5Noda K, Enomoto N, Arai K, Masuda E, Yamada Y, Suzuki K,Tanaka M, Yoshihara H. Induction of antinuclear antibody after interferon therapy in patients with type-C chronic hepatitis: its relation to the efficacy of therapy. Scand J Gastroenterol 1996; 31:716-722.
  • 6Cassani F, Cataleta M, Valentini P, Muratori P, Giostra F, Francesconi R, Muratori L, Lenzi M, Blanch G, Zauli D, Bianchi FB. Serum autoantibodies in chronic hepatitis C: comparison with autoimmune hepatitis and impact on the disease profile.Hepatology 1997; 26:561-566.
  • 7Muratori P, Muratori L, Verucchi G, Attard L, Bianchi FB,Lenzi M. Non-organ-specific autoantibodies in children with chronic hepatitis C: clinical significance and impact on interferon treatment. Clin Infect Dis 2003; 37:1320-1326.
  • 8Agarwal N, Handa R, Acharya SK, Wali JP, Dinda AK,Aggarwal P. A study of autoimmune markers in hepatitis Cinfection. Indian J Med Res 2001; 113:170-174.
  • 9Wada M, Kang KB, Kinugasa A, Shintani S, Sawada K, Nishigami T, Shimoyama T. Does the presence of serum autoaritibodies influence the responsiveness to interferon-alpha 2a treatment in chronic hepatitis C? Intern Med 1997; 36:248-254.
  • 10Wasmuth HE, Stolte C, Geier A, Dietrich CG, Gartung C,Lorenzen J, Matern S, Lammert F. The presence of non-organspecific autoantibodies is associated with a negative response to combination therapy with interferon and ribavirin for chronic hepatitis C. BMC Infectious Diseases 2004; 4:4-12.

共引文献741

同被引文献8

  • 1Kerkar N, Ha&it N, Davies ET, et al. De-novo autoimmune hepatitis after liver transplantation[J]. Lancet, 1998, 351 (9100) : 409-413.
  • 2Salcedo M, Vaquero J, Banares R, et al. Response to steroids in de novo autoimmunehepatitis after liver transplantation [J]. Hepatology, 2002, 35:349-356.
  • 3Salcedo M,Rodriguez-Mahou M,Rodriguez-Sainz C, et al. Risk factors for developing de novo autoimmune hepatitis associated with anti-glutathione S-transferase T1 anti-bodies after liver transplantation[J]. Liver Transpl Surg, 2009, 15 : 530-539.
  • 4Chiu KW, Chen YS, Vanessa H, eta|. Characterization of liver enzymes on living related liver transplantation patients with acute rejection[J]. Hepato Gastroenterology, 2005, 52:1825- 1827.
  • 5Kazuki T, Ken S, Takeo T, et al. De Novo Autoimrnune Hepatitis Subsequent to Switching from Type 2b to Type 2a Alpha-Pegylated Interferon Treatment for Recurrent Hepatitis C After Liver Transplantation: Report of a Case[J]. Surg Today, 2011, 41 : 1016-1019.
  • 6范铁艳,陈虹,沈中阳,田彦,杨洋.小剂量长效干扰素联合利巴韦林治疗肝移植术后丙肝复发[J].武警医学,2013,24(6):507-510. 被引量:4
  • 7李俊,陈虹,范铁艳,王旭.肝移植后肝功能的异常[J].中国组织工程研究,2013,17(31):5686-5692. 被引量:7
  • 8孔祎彬,王绮夏,马雄.肝移植后新发自身免疫性肝炎[J].国际消化病杂志,2013,33(4):238-241. 被引量:5

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部